Design, development and successful application of safe and effective HIV therapeutic and prophylactic vaccines.
- Author:
Jeremiah O A ABALAKA
1
Author Information
1. Medicrest Specialist Hospital, PO Box 382, Gwagwalada-Abuja FCT, Nigeria. medicrestspecialisthospital@yahoo.co.uk
- Publication Type:Journal Article
- MeSH:
AIDS Vaccines;
therapeutic use;
Case-Control Studies;
HIV Antibodies;
blood;
HIV Infections;
immunology;
prevention & control;
therapy;
Hepatitis C Antibodies;
blood;
Humans;
Nigeria;
Serologic Tests
- From:
National Journal of Andrology
2005;11(1):8-16
- CountryChina
- Language:Chinese
-
Abstract:
It is generally held that HIV, the causative agent of the rampaging global HIV/AIDS pandemic, is incurable and uniformly fatal. Since the discovery and isolation of the virus over two decades ago, global efforts at producing preventive and curative vaccines against it have so far resulted in failure. Working single-handedly with only his family's meagre resources and against the tide of universally accepted dogmas on HIV/AIDS, the author designed, developed and applied new HIV therapeutic and preventive vaccines in Nigeria, and has been using them on willing HIV-infected and normal persons respectively with their informed and written consent since their development. In many cases, the therapeutic vaccine produced rapid improvement not only in the symptoms and signs attributable to HIV infection, but also in various laboratory parameters with a sustained seroconversion to HIV antibody negative status in a number of the patients. In those HIV-infected patients with concomitant hepatitis B (HBV) and/or C (HCV) infection(s), the therapeutic vaccine has resulted in maintained seroconversion to negative (normal) for the HBsAg and HCV antibodies also. No significant adverse or side effect has been observed yet with the use of these vaccines. The vaccines do not cause the production of any detectable levels of stigmatizing anti-HIV antibodies. It is postulated that the vaccines elicit effective but selective cell-mediated cytotoxic immune responses against HIV, HBV and HCV-infected cells.
